MyVoice:Rheum Decision Aid for Women With Rheumatic Diseases
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Contraception
- Physician-Patient Relations
- Rheumatic Diseases
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Health Services Research
Participation Requirements
- Age
- Between 18 years and 45 years
- Gender
- Only males
Description
The pilot will demonstrate if the MyVoice decision aid can be feasibly and acceptably implemented into the rheumatology context and inform operational procedures for a future hybrid effectiveness-implementation trial. Women in the intervention arm will receive the MyVoice decision aid (n=38). Women ...
The pilot will demonstrate if the MyVoice decision aid can be feasibly and acceptably implemented into the rheumatology context and inform operational procedures for a future hybrid effectiveness-implementation trial. Women in the intervention arm will receive the MyVoice decision aid (n=38). Women in the control arm (n=12) will receive a widely-accessible paper-based pamphlet about pregnancy, which, similarly to MyVoice, targets women with a broad range of rheumatic diseases. Rheumatologists will have no obligatory actions; however, if one or more of their patients completed the study, they will be emailed an anonymous survey about their experiences with the study and related patient encounters. This will occur 2 weeks after the final patient participant completes the study. Rheumatologists will not be informed by study personnel which of their patients participated in the study.
Tracking Information
- NCT #
- NCT04879745
- Collaborators
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Investigators
- Principal Investigator: Mehret S Birru Talabi, MD, PhD University of Pittsburgh
Get Well Soon